ConcertAI is a leading healthcare technology company specializing in real-world data (RWD) solutions for oncology clinical trials, patient solutions, and research biopharma platforms.

ConcertAI

The fastest growing AI-powered SaaS data company in healthcare. 

AllianceBernstein

Declaration Partners

SymphonyAI

Maverick Ventures

Sixth Street Partners

In this captivating episode of the ConcertAI Podcast, we dive deep with Jennifer R. Rider, ScD, MPH, a renowned cancer epidemiologist. Jennifer shares her journey from academia to the dynamic world of real-world data (RWD) and its vital role in oncology research. We explore how RWD is transforming the landscape of prostate cancer studies and its increasing importance in regulatory decision-making.

Discover how the field of RWD has evolved and its pivotal contributions to the development and application of groundbreaking oncology treatments. Jennifer's insights into the integration of RWD in clinical trials and its potential to shape future cancer therapies are truly enlightening.

Tune in to gain a deeper understanding of the impact and possibilities of real-world data in cancer research and treatment.

Check out the full episode now! Don't forget to subscribe for more insightful discussions on the latest trends in healthcare technology and research.

Listen on Apple Podcasts: https://lnkd.in/gYGYkczc

Listen on Spotify: https://lnkd.in/gjVYeccN

#ConcertAIPodcast #Oncology #RealWorldData #CancerResearch #HealthcareInnovation

We are happy to announce that Dr. Jennifer R. Rider, ScD, MPH, an esteemed cancer epidemiologist, is joining ConcertAI to lead our Real-World Evidence Services. With over two decades of experience, Dr. Rider will spearhead regulatory applications of Real-World Data, impacting oncology trials, breakthrough designations, and regulatory registries.

Boasting an impressive academic background from top institutions like Harvard and Boston University, Dr. Rider returns to ConcertAI, where her oncology RWE journey began in 2020. In her expanded role, she'll also lead the Oncology RWE Leadership Forum, fostering collaboration among industry, academia, and regulatory leaders.

Read the full announcement: https://lnkd.in/gkeZ6f_u 

#RealWorldEvidence #medicalinnovation #leadership


SCOPE 2024 is less than two weeks away! Join us in booth 422 to learn more about our work in oncology clinical trials and our real-world data. At the forefront is our Digital Trial Solution (DTS), a Gen and Predictive AI-enabled Software-as-a-Service suite, which is revolutionizing clinical trial management. DTS harnesses the power of over 8 million records and AI for Study Optimization, enhancing study designs to unprecedented levels of efficiency and effectiveness.

Schedule a meeting with our team: https://lnkd.in/e2eCza7z

#SCOPE2024 #SCOPESummit #clinicaltrials  #healthcareequality  #oncology 

Season Two of The ConcertAI Podcast starts next week! Join us as we explore exciting topics like clinical trial design, multimodal data, and the  latest in healthcare technology.
 
Discover insights on clinical trial advancements and the impact of AI and causal inference in our discussions.
 
Tune in to Apple Podcasts or Spotify for engaging episodes that shape the future of healthcare. Listen now for your dose of innovation and expert analysis.
 
Apple Podcasts: https://lnkd.in/d-MbqAFj
 
Spotify: https://lnkd.in/dfGgZ3bs
 
#podcast #healthcareinnovation #clinicaltrials #RWE #realworldevidence 

"Real-world Homologous Recombination Repair Mutation (HRRm) Testing Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Olaparib in the United States" showcases a groundbreaking use of ConcertAI's Oncology Dataset, presented at the 2024 ASCO Genitourinary Cancers Symposium. Funded by Merck and AstraZeneca, this study offers crucial insights into mCRPC treatment. 

By leveraging ConcertAI's comprehensive Oncology Dataset, the research provides an unparalleled analysis of HRRm testing patterns in mCRPC patients treated with olaparib. This approach highlights the importance of data-driven insights in understanding treatment outcomes and the potential for enhancing patient care through timely genetic testing. 

Join us at the ASCO GU Symposium's Poster Session A: Prostate Cancer to explore how our Oncology Dataset is revolutionizing the landscape of cancer research. This collaborative effort, supported by industry leaders like Merck and AstraZeneca underscores our dedication to harnessing data for advancing cancer treatment. 

Learn more: https://lnkd.in/eHyDwVxv

#ASCO #GU24 #CancerResearch #OlaparibInnovation

Francesca Coutinho

COM:CONCERTAI

ConcertAI